Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05316116 · ClinicalTrials.gov registry record · Early Phase 1
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05316116 is a Early Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT05316116, a Early Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
Interventions
- DRUG Siltuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2024-10-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05316116
The ClinicalTrials.gov registry entry for NCT05316116 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Siltuximab is the first listed.
NCT05316116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05316116 about?
NCT05316116 is a clinical study titled "Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)". The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
What is the current status of trial NCT05316116?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2023-02-15. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT05316116?
The interventions under investigation include: Siltuximab (DRUG).
Who is sponsoring clinical trial NCT05316116?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.